BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

Rescue medications are allowed in the SERENITY study as a safety measure to track inefficacy for patients on placebo. FDA feedback on the TRANQUILITY trial protocol was deemed satisfactory. The company is focused on strengthening its balance sheet and partnership opportunities through ongoing trials.

Read More

Did you find this insightful?